Updated

Sandoz CEO Richard Saynor warned that Trump's proposed tariffs on imported generic drugs could force manufacturers to raise prices or cut supply, ultimately hurting patients who rely on affordable generics. The warning highlights growing concern in the pharmaceutical industry over how trade policy could ripple through to healthcare costs.